Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase I/II study of preoperative treatment with capecitabine, oxaliplatin and irinotecan (XELOXIRI) in patients with advanced colorectal cancer

ABSTRACT: Interventions: Neo-adjuvant chemotherapy : XELOXIRI 6 cycles Resection : total mesorectal excision or tumor-specific mesorectal excision Adjuvant chemotherapy : XELOX 4 cycles Primary outcome(s): 1) Phase I To determine the recommended dose 2) Phase II pathological complete response rate Study Design: Single arm Non-randomized

DISEASE(S): Locally Advanced Rectal Cancer

PROVIDER: 2625365 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase I/II study of preoperative treatment with XELOXIRI(CPT-11, L-OHP, capecitabine) with Cetuximab in patients with RAS wild type-advanced colorectal cancer

Project description:Interventions: Neo-adjuvant chemotherapy : XELOXIRI with Cetuximab 4 cycles Resection : total mesorectal excision or tumor-specific mesorectal excision Adjuvant chemotherapy : XELOX 4 cycles Primary outcome(s): 1) Phase I To determine the recommended dose 2) Phase II pathological complete response rate Study Design: Single arm Non-randomized

| 2647905 | ecrin-mdr-crc

Gene expression profiling of 60 pre-chemotherapy FFPE endoscopic oesophageal adenocarcinoma biopsies

Project description:Oesophageal cancer is the ninth most common cancer in the UK and accounts for 5% of all cancer deaths. The incidence of the disease in men has risen 50% in the last 25 years with the commonest pathological subtype in the West being adenocarcinoma, while in East Asia oesophageal squamous cell carcinoma predominates. Despite efforts to screen for Barrett’s oesophagus, and pre-operatively select OAC patients who are likely to benefit from potentially curative surgery, survival remains poor. The five year survival rate is less than 17% and even in early stage locoregional confined disease this figure lies between 25-35%. A significant improvement in overall survival has been demonstrated with neo-adjuvant or peri-operative chemotherapy but the optimal approach for individual patients remains unclear. A consistent finding has been that complete histopathological response to neo-adjuvant chemotherapy is a prognostic biomarker for increased survival benefit. Therefore, there is a pressing need to identify biomarkers capable of predicting response, enabling clinicians to select patients for whom neo-adjuvant therapies would be beneficial. This experiment represents gene expression profiling of 60 pre-treatment formalin-fixed paraffin embedded (FFPE) oesophageal adenocarcinoma biopsies. All patients were treated with neo-adjuvant cisplatin-based chemotherapy prior to surgical resection at the Northern Ireland Cancer Centre from 2004-2012. The aim of the experiment was to carry out functional enrichment of pathological responders and non-responders to neo-adjuvant chemotherapy in order to identify novel mechanism of drug resistance or chemo-sensitivity.

2018-05-10 | E-MTAB-4666 | biostudies-arrayexpress

A Study of the Gene Expression of Colorectal Liver Metastases: Tumour, ‘Halo’ and Liver Parenchyma

Project description:This was a study comparing the gene expression of liver parenchyma, metastatic colorectal cancer within the liver, and the halo, which is an artifactual area which contained metastatic colorectal cancer before neo-adjuvant chemotherapy reduced the cancer.

2020-05-01 | GSE38174 | GEO

Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer

Project description:RATIONALE: 5FU based neoadjuvant chemoradiation (nCRT) is the standard of care for Stage II/III rectal cancer. Pathologic complete response (pCR) and downstaging have been associated with improved outcomes. The addition of oxaliplatin (OXA) to neoadjuvant therapy may reduce distant disease recurrence. Adjuvant treatment with OXA for rectal cancer has been motivated by benefits demonstrated in stage III colon cancer. Objective: To determine the feasibility, toxicity, and efficacy of preoperative OXA/5FU and RT followed by total mesorectal excision (TME) and adjuvant PURPOSE: This phase II trial is studying the side effects and how well giving neo-adjuvant combination chemotherapy with radiation works in treating patients undergoing surgery for rectal cancer.

| 2066999 | ecrin-mdr-crc

Voorbehandeling met chemotherapie, verwarmde buikspoeling met chemotherapie na chirugische verwijdering van alle tumor bij patienten met buikvlies uizaaiingen van dikke darm of endeldarm kanker.

Project description:Interventions: Neo-adjuvant chemotherapy giving six cycles of oxaliplatin and capecitbine preoperatively followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using mitomycin C. Primary outcome(s): Efficacy of neo-adjuvant chemotherapy with respect to the percentage of patients who are resectable after neo-adjuvant chemotherapy. Study Design: N/A: single arm study, Open (masking not used), N/A , unknown, Factorial

| 18100 | ecrin-mdr-crc

Identification of the molecular signature of distinctive breast cancer associated fibroblasts (CAFs)

Project description:Cancer associated fibroblasts (CAFs) are highly heterogeneous and different subsets of CAFs may exhibit distinct functions, To identify the molecular signature of distinctive CAFs , we compared mRNA expression profiles of CAFs isolated from tumors in sensitive patients and resistant ones before neo-adjuvant chemotherapy. Compared the CAFs from sensitive samples, those from refractory samples exhibited a distinctive signature.

2018-01-08 | GSE108565 | GEO

Expression data from 43 Ovarian tumors

Project description:Gene expression profiles of malignant carcinomas surgically removed from ovarian cancer patients pre-treated with chemotherapy (neo-adjuvant) prior to surgery group into two distinct clusters. One group clusters with carcinomas from patients not pre-treated with chemotherapy prior to surgery (C-L) while the other clusters with non-malignant adenomas (A-L). Although the C-L cluster is preferentially associated with p53 loss-of-function (LOF) mutations, the C-L cluster cancer patients display a more favorable clinical response to chemotherapy as evidenced by enhanced long-term survivorships. Keywords: Patient Tumor Samples

2007-05-31 | GSE7463 | GEO

microRNA expression profiling of early primary breast cancer to identify prognostic markers and associated pathways

Project description:Retrospective series of primary breast cancer patients who received surgery between 1989 and 1992. Patients received adjuvant chemotherapy and/or adjuvant hormone therapy, or no adjuvant treatment. Tamoxifen was used as endocrine therapy for 5 years in ER+ BC patients. Patients who were <50 years of age, with lymph node positive tumors, or ER– and/or >3 cm in diameter, received adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for six cycles, in a thrice weekly intravenous regimen. Patients >50 years of age with ER–, lymph node–positive tumors also received CMF.

2011-07-08 | GSE22216 | GEO

Gene expression profiling of early primary breast cancer to identify prognostic markers and associated pathways

2011-07-08 | GSE22219 | GEO

Oesophageal cancer neo-adjuvant

Project description:Oesophageal adenocarcinoma exome sequence data from samples before and after neo-adjuvant chemotherapy

| PRJEB12657 | ENA